Topiramate: current status and therapeutic potential

Bibliography

• Papers of special note have been highlighted as of interest of considerable interest
   Google Scholar
• BRODIE MJ, DICHTER MA: Antiepileptic drugs. New Engl. J. Med. (1996) 334:168–175.
   PubMed Web of Science ®Google Scholar
• DICHTER MA, BRODIE MJ: New antiepileptic drugs. New Engl. J. Med. (1996) 334:1583-1590.
   Google Scholar
• BAKER GA, JACOBY A, BUCK D, STALGIS C, MONNET D: Quality of life of people with epilepsy: a European study. Epilepsia (1997) 38:353–362.
   PubMed Web of Science ®Google Scholar
• BEN-MENACHEM E, HENRIKSEN 0, DAM M etal.: Doubleblind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia (1996) 37:539-543.
   Google Scholar
• One of 5 pivotal controlled trials establishing the efficacy and safety of TPM add-on therapy in adults with partial-onset seizures.
   Google Scholar
• TASSINARI CA, MICHELUCCI R, CHAUVEL P etal.: Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia (1996) 37:763–768.
   Google Scholar
• One of 5 pivotal controlled trials establishing the efficacy and safety of TPM add-on therapy in adults with partial-onset seizures.
   Google Scholar
• SHARIEF M, VITERI C, BEN-MENACHEM E et al.: Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res. (1996) 25:217–224.
   Google Scholar
• One of 5 pivotal controlled trials establishing the efficacy and safety of TPM add-on therapy in adults with partial-onset seizures.
   Google Scholar
• FAUGHT E, WILDER BJ, RAMSAY REet al.: Topiramate placebo-controlled dose-ranging trial in refractory par-tial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology (1996) 46:1684-1690.
   Google Scholar
• One of 5 pivotal controlled trials establishing the efficacy and safety of TPM add-on therapy in adults with partial-onset seizures.
   Google Scholar
• PRIVITERA M, FINCHAM R, PENRY J et al.: Topiramate placebo-controlled dose-ranging trial in refractory par-tial epilepsy using 600-, 800-, and 1000-mg daily dos-ages. Neurology (1996) 46:1678-1683.
   Google Scholar
• One of 5 pivotal controlled trials establishing the efficacy and safety of TPM add-on therapy in adults with partial-onset seizures.
   Google Scholar
• MARYANOFF BE, NORTEY SO, GARDOCKI JF, SHANK RP,
   Google Scholar
• DODGSON SP: b>Anticonvulsant 0-alkyl sulfamates. 2,3:4,5-bis- 0- (1-methylethylidene)-P-D-fructopyranose sulfamate (McN-4853) and related compounds. J. Merl. Chem. (1987) 30:880–887.
   PubMed Web of Science ®Google Scholar
• GARDOCKI JF, LABINSKY LS, BROWN GL, MARYANOFF BE: Anticonvulsant activity of McN-4853 (M) 2,3:4,5-bis-0-(L-methylethylidene)-3-D-fructopyranose sulfamate in mice and rats. Epilepsia (1986) 27:648–649.
   Web of Science ®Google Scholar
• KIMISHIMA K, WANG Y, TANABE K: Anticonvulsant ac-tivities and properties of topiramate. Jpn. J. Pharmacol (1992) 58\(Suppl. 1):211P.
   Google Scholar
• WAUQUIER A, ZHOU S: Topiramate: a potent anticon-vulsant in the amygdala-kindled rat. Epilepsy Res. (1996) 24:73–77.
   PubMed Web of Science ®Google Scholar
• NAKAMURA F, HIYOSHI T, KUDO T, YAGI K, SEINO M:Anticonvulsant effect of topiramate [2,3:4,5-bis-0-(1-methylethylidene-3-D -fructopy ranose sulfate] on amygdaloid kindled seizures in the cat. Jpn. J. Psychial Neurol. (1993) 47:394–395.
   PubMed Web of Science ®Google Scholar
• EDMONDS HL, JIANG YD, ZHANG PY, SHANK RP: Anti-convulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy. Life Sci. (1996) 59(10)127–131.
   Web of Science ®Google Scholar
• VAUGHT JL, MARYANOFF BE, SHANK RP: The pharma-cological profile of topiramate: a structurally novel, clinically effective anticonvulsant. Epilepsia (1991) 32(Suppl. 3):19.
   Google Scholar
• SHANK RP, GARDOCKI JF, VAUGHT JLet al: Topiramate: preclinical evaluation of a structurally novel anticon-vulsant. Epilepsia (1994) 35:450–460.
   PubMed Web of Science ®Google Scholar
• WHITE HS, WOODHEAD J, WOLF HH: Effect of topi-ramate (TPM) on pentylenetetrazol (PTZ) seizure threshold. Epilepsia (1996) 37 (Suppl. 5):26.
   Google Scholar
• NAKAMURA J, TAMURA S, KANDA T et al.: Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol (1994) 254:83–89.
   PubMed Web of Science ®Google Scholar
• COULTER DA, SOMBATI S, DELORENZO RJ: Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neu-rons. Epilepsia (1993) 34 (Suppl. 2):123.
   Google Scholar
• SOMBATI S, COULTER DA, DELORENZO RJ: Effects of topiramate on sustained repetitive firing and low Mg-induced seizure discharges in cultured hippocampal neurons. Epilepsia (1995) 36\(Suppl. 4):38.
   Google Scholar
• WHITE HS, BROWN SD, WOLF HH, TWYMAN RE: The anticonvulsant topiramate potentiates GABA-evoked chloride current in mouse cortical neurons. Epilepsia (1994) 35\(Suppl. 8):67.
   Google Scholar
• COULTER DA, SOMBATI S, DELORENZO RJ: Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents. Epilepsia (1995) 36\(Suppl. 3):540.
   Google Scholar
• PIM-GARZA JE, MCLEAN MJ: Different effects of topi-ramate and phenytoin on mouse seizures and re-sponses of cultured neurons to excitatory amino acids. Epilepsia (1996) 37 (Suppl. 5):26.
   Google Scholar
• SHANK RP, VAUGHT JL, RAFFA RB, MARYANOFF BE: Investigation of the mechanism of topiramate's anti-convulsant activity. Epilepsia (1991) 32 (Suppl. 3):7–8.
   Google Scholar
• EASTERLING DE, ZAKSZEWSKI T, MOYER MDet al.: Plasma pharmacokinetics oftopiramate, a new anticon-vulsant in humans. Epilepsia (1988) 29(5):662.
   Google Scholar
• NAYAK RK, GISCLON LG, CURTIN CA, BENET LZ: Estima-tion of the absolute bioavailability of topiramate in humans without intravenous data. J. Chn. Pharmacol. (1994) 34:1029.
   Google Scholar
• BIALER M: b>Comparative pharmacokinetics of the newer antiepileptic drugs. C7in. Pharmacokinet. (1993) 24 (6):441–452.
   Google Scholar
• DOOSE DR, SCOTT W, MARGUL BL, MARRIOTT TB, NAYAK RK: Multiple-dose pharmacokinetics of topi-ramate in healthy male subjects. Epilepsia (1988) 29(5)662.
   Web of Science ®Google Scholar
• DOOSE DR, GISCLON LG, STELLAR SM, RIFFITS JM, HILLS JF: The effect of food on the bioavailability of topiram ate from 100- and 400-mg tablets in healthy male subjects. Epilepsia (1992) 33 (Suppl. 3):105.
   Google Scholar
• SACHDEO RC, SACHDEO SK, WALKER SAet al.: Steady-state pharmacokinetics of topiramate and car-bamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia (1996) 37:774–780.
   PubMed Web of Science ®Google Scholar
• GISCLON LG, CURTIN CR, KRAMER LD: The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin®) and of topiramate (Topamax®) in epileptic patients on monotherapy, and during combination therapy. Epilep-sia (1994) 35\(Suppl. 8):54.
   Google Scholar
• GISCLON LG, RIFFITTS JM, SICA DA, GEHR T, RUDDLEY J: The pharmacokinetics (PK) of topiramate (T) in sub-jects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF). Pharm. Res. (1993) 10(Suppl.):5397.
   Google Scholar
• GISCLON LG, CURTIN CR: The pharmacokinetics (PK) of topiramate (T) in subjects with end-stage renal disease undergoing hemodialysis. Clin. Pharmacol. Ther. (1994) 55(2):196. Abstract PIII–56.
   Google Scholar
• DOOSE DR, WALKER SA, VENKATARAMANAN R, RABI-NOVITZ M, LEVER J: Topiramate pharmacokinetics in
   Google Scholar
• subjects with liver impairment. Pharm. Res. (1994) 11 (Suppl.) :S446.
   Google Scholar
• ROSENFELD WE, LIAO S, KRAMER LDet al.: Comparisonof the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during mono-therapy and concomitant therapy. Epilepsia (1997) 38:324–333.
   PubMed Web of Science ®Google Scholar
• DOOSE DR, WALKER SA, PLEDGER G, LIM P, REIFE RA:Evaluation of phenobarbital and p rimidone/phenobar-bital (primidone's active metabolite) plasma concentra-tions during administration of add-on topiramate therapy in five multicenter, double-blind, placebo-con-trolled trials in outpatients with partial seizures. Epilep-sia (1995) 36\(Suppl. 3):S158.
   Google Scholar
• LEVY RH, BISHOP F, STREETER AJet al.: Explanation andprediction of drug interactions with topiramate using a CYP450 inhibition spectrum. Epilepsia (1995) 36\(Suppl. 4):47.
   PubMedGoogle Scholar
• LIAO S, PALMER M: Digoxin and topiramate drug inter-action study in male volunteers. Pharm. Res. (1993) 10(Suppl.):S405.
   Google Scholar
• ROSENFELD WE, DOOSE DR, WALKER SA, NAYAK RK: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia (1997) 38:317–323.
   PubMed Web of Science ®Google Scholar
• ROSENFELD WE, DOOSE DR, WALKER SA, SCHAEFER P, REIFE RA: Steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epi-lepsy. Epilepsia (1995) 36(Suppl. 3):S158.
   Google Scholar
• THE US GABAPENTIN STUDY GROUP NO. 5: Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology (1993) 43:2292-2298.
   Google Scholar
• MATSUO F, BERGEN D, FAUGHT E et al.: Placebo-control-led study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology (1993) 43:2284–2291.
   PubMed Web of Science ®Google Scholar
• PLEDGER G, REIFE RA, LIM P, KARIM R: Overview oftopiramate efficacy from adjunctive therapy trials. Epi-lepsia (1995) 36\(Suppl. 3):5150.
   Google Scholar
• PROEST G, STEINBOFF S, RIED S, SCHEULER W, OTT B: Open add-on trial with topiramate (Topamax) in pa-tients with partial epilepsy. Epilepsia (1995) 36\(Suppl. 3):S151.
   PubMedGoogle Scholar
• GUIDOLIN L, CANEVINI MP, SGRO V eta].: Topiramate as add-on therapy in drug-resistant partial epilepsies. Epi-lepsia (1995) 36\(Suppl. 3):S151.
   Web of Science ®Google Scholar
• TARTARA A, SARTORI I, MANNI R et al.: Add-on trial of topiramate in refractory epilepsy. Epilepsia (1995) 36(Suppl. 3):S150.
   Google Scholar
• PAVKOVIC I, SACKELLARES C, BEYDOUN A: Efficacy and safety of topiramate in epilepsy. Epilepsia (1995) 36\(Suppl. 4):55.
   Google Scholar
• PRIVITERA M: Long-term efficacy and safety of topi-ramate. Epilepsia (1995) 36(Suppl. 3):S152.
   Google Scholar
• BEN-MENACHEM E: Long-term follow-up of patients treated with topiramate for partial seizures. Epilepsia (1995) 36\(Suppl. 3):5152.
   Google Scholar
• © Ashley Publications Ltd. All rights reserved.
   Google Scholar
• MICHELUCCI R, PASSARELLI D, TASSINARI CA: Topiramate in the treatment of refractory partial epilepsy: a dou-ble-blind study with long-term follow-up. Epilepsia (1995) 36\(Suppl. 3):S150.
   Google Scholar
• FINCHAM RW, SCHOTTELIUS DD: Long-term therapy with topiramate in patients with partial seizures. Epilep-sia (1995) 36\(Suppl. 4):56.
   Google Scholar
• MIKKELSEN M, OSTERGAARD L, DAM M: Topiramate as long-term treatment in refractory partial epilepsy. Epi-lepsia (1993) 34 (Suppl. 2):123.
   Google Scholar
• KAMIN M, ABOU-KHALIL B, THE YOL TOPIRAMATE STUDY TEAM: Long-term efficacy in an open-label trial of topiramate. Epilepsia (1996) 37 (Suppl. 5):168.
   Google Scholar
• ROSENFELD WE, SACHDEO RC: Topiramate can be a successful monotherapy drug. Epilepsia (1995) 36\(Suppl. 4):56.
   Google Scholar
• SACHDEO RC, REIFE RA, LIM P, PLEDGER G: Topiramate monotherapy for partial onset seizures. Epilepsia (1997) 38:294–300.
   PubMed Web of Science ®Google Scholar
• MARSON AG, KADIR ZA, CHADWICK DW: New antiepi-leptic drugs: a systematic review of their efficacy and tolerability. Br. Med. J. (1996) 313:1169–1174.
   PubMed Web of Science ®Google Scholar
• ELFERINK AJA, VAN ZWEITEN-BOOT BJ: Analysis based on number needed to treat shows differences between drugs studied. Br. Med. J. (1997) 314:603.
   Web of Science ®Google Scholar
• BEN-MENACHEM E: Potential antiepileptic drugs: topi-ramate. In: Antiepileptic Drugs(Fourth Edition). Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York (1995):1063–1070.
   Google Scholar
• SHORVON SD: Safety of topiramate: adverse events and relationships to dosing. Epilepsia (1996) 37 (Suppl. 2):518–22.
   Google Scholar
• REIFE RA, LIM P, PLEDGER G: Topiramate: side-effect profile in double-blind studies. Epilepsia (1995) 36\(Suppl. 4):34.
   Google Scholar
• WASSERSTEIN AG, RAK I, REIFE RA: Nephrolithiasis dur-ing treatment with topiramate. Epilepsia (1995) 36\(Suppl. 3):S153.
   Google Scholar
• WASSERSTEIN AG, RAK I, REIFE RA: Investigation of themechanistic basis for topiramate-associated nephrolithiasis: examination of urinary and serum constitu-ents. Epilepsia (1995) 36\(Suppl. 3):S153.
   Google Scholar
• PRIVITERA M: Long-term cognitive effects of top irarnate. Epilepsia (1995) 36\(Suppl. 3):S152.
   Google Scholar
• BURTON L, HARDEN CL: Effects of topiram ate on atten-tion over time. Epilepsia (1994) 35 (Suppl. 8):116.
   Google Scholar
• ESPE-LILLO J, RITTER FJ, FROST MD, SPIEGEL RH, REIFE R: Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types. Epilepsia (1995) 36\(Suppl. 4):56.
   Google Scholar
• THANEDAR S, ROSENFELD WE: Topiramate well toler-ated by pediatric patients. Epilepsia (1995) 36\(Suppl. 4)34.
   Google Scholar
• ROSENFELD WE. In discussion: Topiramate: Pharmacokinet-ics, Efficacy and Tolerability. Dodson WE, Shorvon SD (Eds.), Royal Society of Medicine Press Ltd., London (1996). Round Table Series 40: 21–22.
   Google Scholar
• FRENCH JA, BOURGEOIS BFD, DREIFUSS FEet al.: An open-label multicenter study of topiramate in patients with Lennox-Gastaut syndrome. Neurology (1995) 45\(Suppl. 4):A250.
   Google Scholar
• GLAUSER TA: Topiramate. Seminars in Pediatric Neurology (1997). In press.
   PubMedGoogle Scholar
• SACHDEO SK, SACHDEO RC, KUGLER SL: An open label evaluation of topiramate in Lennox-Gastaut syndrome. Epilepsia (1996) 37 (Suppl. 5):112.
   Google Scholar
• BITON V, REIFE R, KAMIN M, BOB ROSKY K: Topiramate (Topamax®) as add-on therapy for patients with pri-mary generalized epilepsy. Neurology (1996) 46:A176.
   Google Scholar
• REIFE RA, PLEDGER G, DOOSE D, LIM P, WARD C: Topi-ramate: PK/PD analyses. Epilepsia (1995) 36\(Suppl. 3):S152.
   Google Scholar
• BEN-MENACHEM E. In discussion: Topiramate: Pharmacok-inetics, Efficacy and Tolerability Dodson WE, Shorvon SD (Eds.), Royal Society of Medicine Press Ltd., London (1996). Round Table Series 40: 36–37.
   Google Scholar